Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Paracetamol Stories

2013-08-15 23:27:21

Most recent court statistics show that number of cases in multidistrict litigation has grown to 80. Resource4thePeople also announces that its nationwide network of attorneys is continuing to offer free consultations to consumers over allegations that Tylenol and other acetaminophens may cause liver cancer. San Diego, CA (PRWEB) August 15, 2013 http://www.resource4thepeople.com/defectivedrugs/acetaminophen.html Resource4thePeople today announced today its latest update about lawsuits...

2013-08-15 16:24:13

SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that the United States Patent and Trademark Office (USPTO), has issued a non-final, initial office action in the Ex Parte Reexamination of US Patent No. 6,028,222, or the '222 patent, one of the two licensed patents covering OFIRMEV(®) (acetaminophen) injection. Although the USPTO made an initial determination to reject certain claims, all of the claims of the '222 patent remain...

2013-08-14 08:29:50

Ampion Study Meets Primary Endpoint with High Statistical Significance; All Primary Study Objectives were Achieved GREENWOOD VILLAGE, Colo., Aug. 14, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results from the SPRING study (clinicaltrials.gov NCT01839331) of Ampion for the treatment of osteoarthritis of the knee (OAK). In this study of 329 patients, patients treated with a single intra-articular injection of Ampion achieved a clinically...

2013-08-06 16:28:35

- Caldolor pediatric fever study completed with positive top-line results. NASHVILLE, Tenn., Aug. 6, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2013 financial results. Net Revenue: For the three months ended June 30, 2013, net revenue was $7.1 million compared to $12.4 million for the prior year period. Net revenue was $4.1 million for...

2013-08-03 23:01:02

Transparency Market Research adds new "Pain Management Therapeutics Market (Anticonvulsants, Antidepressants, Anesthetics, NSAIDs, Opioids, Other Non-Narcotic Analgesics and Anti-Migraine Agents) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018" market research report to its report store. To browse the report, visit http://www.transparencymarketresearch.com/pain-management-therapeutics.html. Albany, New York (PRWEB) August 03, 2013 Transparency...

Skin Rash, Blisters, Disease Associated With Acetaminophen Use
2013-08-02 11:11:23

Lawrence LeBlond for redOrbit.com - Your Universe Online Acetaminophen has been a widely-used source of pain relief and fever reducer for decades. However, a number of studies have linked the popular drug to illnesses such as liver toxicity and the US Food and Drug Administration (FDA) has, in the past, considered restricting its use in both generic and brand name formulas, which includes Tylenol. Now, new warnings by the FDA may give consumers another reason to shy away from the use of...

Doctors Often Neglect Back Pain Treatment Guidelines
2013-08-01 10:06:15

Brett Smith for redOrbit.com - Your Universe Online Back pain is the fifth most common reason Americans visit their doctor, spending around $86 million annually. A new study suggests that doctors could improve treatment and reduce waste by simply following national guidelines when treating these patients. "Back pain treatment is costly and frequently includes overuse of treatments that are not supported by clinical guidelines, and that don't impact outcomes," said study co-author Dr....

2013-07-31 12:27:23

MUMBAI and BALTIMORE, July 31, 2013 /PRNewswire/ -- elsPharma Major Lupin Limited announced today that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration (FDA). Lupin's...

2013-07-31 08:28:34

ALBANY, New York, July 31, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47...

2013-07-29 08:27:02

Controlled Substance Analgesic Combination Product Uses Depomed's Proprietary Acuform® Technology NEWARK, Calif., July 29, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795. MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe acute...